Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
The latest Employment Situation report from the Bureau of Labor Statistics shows that employment for healthcare workers is slowly but surely returning to its pre-pandemic levels.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
HRA Pharma, a Perrigo company, has submitted an application to the FDA seeking approval for the country’s first-ever over-the-counter (OTC) birth control pill.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.
Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.
A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.
